References
- Labiris NR , DolovichMB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol.56(6), 588–599 (2003).
- DiMasi JA , GrabowskiHG. The cost of biopharmaceutical R&D: is biotech different? Manage Decis. Econ.28, 469–479 (2007).
- Egerton M . Pressure on the Pipeline. International Clinical Trials.82–84, February (2012).
- Paul SM , MytelkaDS, DunwiddieCT, PersingerCC, MunosBH, LindborgSR. How to improve R&D productivity: the pharmaceutical industry‘s grand challenge. Nat. Rev. Drug Discov.9, 203–214 (2010).
- Patrick LJ , ConnorAL, MairSJ, CollierJE, RonanoM, HanrahanJ. Design and implementation of a multi-part, flexible protocol to assess the tolerability and pharmacodynamic effects of PUR118 in healthy subjects and COPD patients. Presented at: European Respiratory Society Annual Congress. Vienna, Austria, 1–5 September 2012.
- Lobo ED , ArgentineMD, SperryDCet al. Optimization of LY545694 tosylate controlled release tablets through pharmacoscintigraphy. Pharm. Res. 29, 2912–2925 (2012).
- Lin W , SchuellerO, PatelA, McDermottJ, SweetnamP, ScholesP. Development of a formulation design space for SLx-2101 modified release tablets to enable a flexible Phase I pharmacokinetic study. Poster #583. Presented at: Annual Exposition of the Controlled Release Society (CRS), OR, USA, 10–14 July, 2010.
Website
- Scholes PD. RapidFACT – a new paradigm for the effective optimisation of oral dosage forms. Quotient Clinical White Paper, 2008. www.quotientbioresearch.com/publications/white-papers